China

Drugmakers slash prices to be eligible for China’s bulk-buy program
Drugmakers slash prices to be eligible for China’s bulk-buy program
CNBC
China
off-patent
bulk-buy
Flag link:
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
Fierce Biotech
IPOs
China
NASDAQ
I-Mab Biopharma
autoimmune disease
cancer
Flag link:
Innovent and Coherus Strike Licensing Agreement for Avastin Biosimilar
Innovent and Coherus Strike Licensing Agreement for Avastin Biosimilar
BioSpace
China
Innovent Biologics
Coherus Biosciences
biosimilars
Avastin
Flag link:
China’s CF PharmTech Raises $90M to Advance Respiratory Drug Development
China’s CF PharmTech Raises $90M to Advance Respiratory Drug Development
Xconomy
China
CF PharmTech
respiratory disease
drug development
Flag link:
AstraZeneca kicks off 2020 with double win in US and China
AstraZeneca kicks off 2020 with double win in US and China
Pharmaforum
AstraZeneca
FDA
Farxiga
heart failure
China
Lokelma
hyperkalemia
Flag link:
Homegrown rivals to Pfizer, Merck cash cow vaccines win nods in China
Homegrown rivals to Pfizer, Merck cash cow vaccines win nods in China
Fierce Pharma
Pfizer
Merck
Prevnar 13
Gardasil
vaccines
China
Walvax
Flag link:
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Xtalks
Amgen
BeiGene
oncology
China
Flag link:
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market
Pharmaforum
Boehringer Ingelheim
China
BeiGene
drug manufacturing
Flag link:
Four Major Biopharma Scandals in 2019
Four Major Biopharma Scandals in 2019
BioSpace
scandal
Novartis
Zolgensma
data manipulation
China
CRISPR
IP theft
Purdue Pharma
Sackler family
oxycontin
Flag link:
Joinn Biologics nabs $60M to use for biologics capacity
Joinn Biologics nabs $60M to use for biologics capacity
Fierce Pharma
Joinn Biologics
China
CDMO
drug manufacturing
biologics
Flag link:
Pharma fury as Trump’s team reneges on biologic patent rules in trade talks
Pharma fury as Trump’s team reneges on biologic patent rules in trade talks
Pharmaforum
trade
biologics
drug pricing
regulatory
Canada
Mexico
China
Flag link:
AZ’s Imfinzi approved in early lung cancer in China
AZ’s Imfinzi approved in early lung cancer in China
Pharmaforum
China
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:
Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors
Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors
Motley Fool
Merck
Keytruda
vaccines
China
Flag link:
Drugs firms make massive discounts to get reimbursement in China
Drugs firms make massive discounts to get reimbursement in China
Pharmaforum
Roche
Novartis
China
reimbursement
Flag link:
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Endpoints
Roche
Tecentriq
Avastin
liver cancer
China
Bayer
Nexavar
clinical trials
Flag link:
Brii bags rights to tuberculosis drug to further antibiotic push
Brii bags rights to tuberculosis drug to further antibiotic push
Fierce Biotech
Brii Biosciences
China
AN2 Therapeutics
tuberculosis
antibiotics
Flag link:
OxyContin maker thrives in China with abandoned U.S. tactics
OxyContin maker thrives in China with abandoned U.S. tactics
Stat
Purdue Pharma
Sackler family
China
oxycontin
opioids
opioid crisis
Mundipharma
Flag link:
Novartis Cuts 150 Jobs As it Shifts Focus of Shanghai Facility to Drug Development
Novartis Cuts 150 Jobs As it Shifts Focus of Shanghai Facility to Drug Development
BioSpace
Novartis
Shanghai
China
layoffs
R&D
Flag link:
China's BeiGene gets FDA approval for drug to treat rare form of lymphoma
China's BeiGene gets FDA approval for drug to treat rare form of lymphoma
Yahoo/Reuters
BeiGene
China
FDA
Brukinsa
mantle cell lymphoma
Flag link:
Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1
Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1
Endpoints
China
BeiGene
Amgen
tislelizumab
anti-PD-L1
Flag link:

Pages